Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD70 CAR-T in Relapsed/Refractory Lymphoma
NCT05948033Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD70 CAR-T cells in lymphoma, sponsored by Chinese PLA General Hospital. Primary endpoints: Incidence of treatment related adverse events at 12 months, Incidence of dose limiting toxicities at 28 days and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
CD70 CAR-T cells
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT05948033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05948033.